Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Lower Sales, Greater R&D Spending, Widened Loss in Q2

NEW YORK, Aug. 2 - Transgenomic reported that an increase in second-quarter R&D spending and a dip in sales caused a sharp jump in net loss.


Net sales in the period ended June 30 fell to $9.4 million from $9.5 million one year ago, the company said.


Meantime, R&D spending climbed to $3 million from $2.2 million in the second quarter 2001. As a result, net loss surged to $4 million, or $.17 per share, from $1.6 million, or $.07 per share, year over year, Transgenomic said on Wednesday.


The company said it had roughly $25 million in cash, cash equivalents, and short-term investments.


Click here for more information.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.